Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose IVIG and rituximab in kidney transplant patients with de novo donor-specific antibodies
KCT0010459Phase 4Completed
- Sponsor
- GC Biopharma
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of immune globulin, rituximab in Kidney allograft status (RTx), sponsored by GC Biopharma. Started Jan 2019; status: completed.
02
Drugs
immune globulinrituximab
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on KCT0010459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010459.